Paula Paulo

This study identifies CD276 as a glycosylation-dependent immune checkpoint in colorectal cancer that promotes aggressiveness and immune escape by altering T-cell activation and cytokine production.

This paper evaluates how sample size affects polygenic hazard score models for prostate cancer, finding that 20-30k samples are needed for discovery models, but 10k suffice if SNPs are pre-established.

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

This paper develops a genetic risk score to personalize prostate cancer screening age based on polygenic hazard scores and validates its predictive power in a separate dataset.